Abstract: It is to provide a novel LXRß agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis; arteriosclerosis such as those resulting from diabetes; dyslipidemia; hypercholesterolemia; lipid-related diseases; inflammatory diseases that are caused by inflammatory cytokines; skin diseases such as allergic skin diseases; diabetes; or Alzheimer's disease. It is a carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.
| # | Name | Date |
|---|---|---|
| 1 | 8314-DELNP-2010-GPA-(18-01-2011).pdf | 2011-01-18 |
| 2 | 8314-DELNP-2010-Form-1-(18-01-2011).pdf | 2011-01-18 |
| 3 | 8314-DELNP-2010-Correspondence-Others-(18-01-2011).pdf | 2011-01-18 |
| 4 | 8314-DELNP-2010-Correspondence-Others-(23-02-2011).pdf | 2011-02-23 |
| 5 | 8314-DELNP-2010-Form-3-(20-05-2011).pdf | 2011-05-20 |
| 6 | 8314-DELNP-2010-Correspondence-Others-(20-05-2011).pdf | 2011-05-20 |
| 7 | abstract.jpg | 2011-08-20 |
| 8 | 8314-delnp-2010-form-5.pdf | 2011-08-20 |
| 9 | 8314-delnp-2010-form-3.pdf | 2011-08-20 |
| 10 | 8314-delnp-2010-form-2.pdf | 2011-08-20 |
| 11 | 8314-delnp-2010-form-1.pdf | 2011-08-20 |
| 12 | 8314-delnp-2010-description (complete).pdf | 2011-08-20 |
| 13 | 8314-delnp-2010-correspondence-others.pdf | 2011-08-20 |
| 14 | 8314-delnp-2010-claims.pdf | 2011-08-20 |
| 15 | 8314-delnp-2010-abstract.pdf | 2011-08-20 |
| 16 | 8314-delnp-2010-Form-18-(27-04-2012).pdf | 2012-04-27 |
| 17 | 8314-delnp-2010-Correspondence-Others-(27-04-2012).pdf | 2012-04-27 |
| 18 | 8314-dekbo-2010-Form-13-(17-05-2012).pdf | 2012-05-17 |
| 19 | 8314-dekbo-2010-Correspondence Others-(17-05-2012).pdf | 2012-05-17 |
| 20 | 8314-delnp-2010-PCT-373.pdf | 2015-10-07 |
| 21 | 8314-delnp-2010-PCT-338.pdf | 2015-10-07 |
| 22 | 8314-delnp-2010-PCT-237.pdf | 2015-10-07 |
| 23 | 8314-delnp-2010-PCT-210.pdf | 2015-10-07 |
| 24 | 8314-DELNP-2010-FER.pdf | 2017-02-03 |
| 25 | 8314-DELNP-2010-AbandonedLetter.pdf | 2017-11-13 |
| 1 | 8314search_03-02-2017.pdf |